Regulus Therapeutics Inc. (NASDAQ:RGLS)’s share price was down 4% during mid-day trading on Thursday . The stock traded as low as $3.31 and last traded at $3.34, with a volume of 578,829 shares traded. The stock had previously closed at $3.48.

Several equities analysts have recently issued reports on RGLS shares. BMO Capital Markets started coverage on shares of Regulus Therapeutics in a research note on Monday, April 11th. They issued an “outperform” rating and a $16.00 price objective on the stock. Zacks Investment Research cut shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. FBR & Co reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Regulus Therapeutics in a research note on Thursday, June 2nd. Cowen and Company reaffirmed a “buy” rating on shares of Regulus Therapeutics in a research note on Wednesday, June 8th. Finally, Chardan Capital started coverage on shares of Regulus Therapeutics in a research note on Wednesday, April 13th. They issued a “buy” rating and a $15.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Regulus Therapeutics currently has an average rating of “Buy” and a consensus target price of $10.42.

The stock’s market capitalization is $184.73 million. The company has a 50-day moving average of $5.06 and a 200 day moving average of $6.35.

Regulus Therapeutics (NASDAQ:RGLS) last issued its earnings results on Monday, May 2nd. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by $0.07. On average, equities analysts predict that Regulus Therapeutics Inc. will post ($1.54) EPS for the current year.

An institutional investor recently bought a new position in Regulus Therapeutics stock. Oxford Asset Management acquired a new stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 260,798 shares of the biopharmaceutical company’s stock, valued at approximately $2,335,000. Oxford Asset Management owned approximately 0.50% of Regulus Therapeutics at the end of the most recent reporting period.

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.